Striatal dopamine transporter in Parkinson's disease: A study with a new radioligand, [123I]B-CIT-FP

Parkinsonism and Related Disorders

Volumn 3, Issue 2, 1997, Pages 77-81

  Rinne, Juha O ^a   Kuikka, Jyrki T ^b   Bergström, Kim A ^b   Hiltunen, Jukka ^c   Kilpelainen, Hannu ^d  

^a UNIVERSITY OF TURKU   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c MAP Medical Technologies Oy   (Finland)

^d Savonlinna Central Hospital   (Finland)

Author keywords

CIT; Dopamine reuptake sites; Monoamine transporter; Parkinson's disease; Positron emission tomography; Single photon emission tomography

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; IODINE 123; LEVODOPA; NORTROPANE DERIVATIVE; RADIOLIGAND; TOSYLCHLORAMIDE SODIUM;

ADULT; ARTICLE; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORPUS STRIATUM; DISABILITY; DOPAMINE UPTAKE; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PUTAMEN; RADIATION EXPOSURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0031426062     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(96)00046-6     Document Type: Article

References (25)

1. Garnett E. S., Nahmias C., Firnau G. Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Canadian Journal of Neurological Science 1984; 11: 174-179.
2. Leenders K. L., Palmer A. J., Quinn N., et al. Brain dopamine metabolism in patients with parkinson's disease measured with positron emission tomography. Journal of Neurology, Neurosurgery and Psychiatry 1986; 49: 853-860.
3. Martin, W. R. W., Adam, M. J., Bergström, M., et al. In vivo study of DOPA metabolism in Parkinson's disease. In Recent Developments in Parkinson's Disease, ed. S. Fahn, C. D. Marsden, P. Jenner, P. Teychenne. Raven Press, New York, 1986, pp. 97-102.
4. 11C]β-CIT in Parkinson's disease. Journal of Nuclear Medicine 1995; 36: 1263-1267.
5. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Annals of Neurology 1993; 43: 423-431.
6. 11C]β-CFT in early Parkinson's disease. Synapse 1995; 21: 97-103.
7. 123I]-2-β-carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT): high affinity SPECT radiotracer of monoamine reuptake sites in brain. Journal of Medical Chemistry 1991; 34: 3144-3146.
8. Innis R. B., Seibyl J. P., Scanley B. E., et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proceedings of the National Academy of Sciences U.S.A. 1993; 90: 11965-11969.
9. Brücke T., Asenbaum S., Pozzera A., et al. Dopaminergic nerve cell loss in Parkinson's disease quatified with [I-123]-β-CIT ans SPECT correlates with clinical findings. Movement Disorders 1994; 9 (Suppl 1): 120.
10. Kuikka J. T., Bergström K. A., Vanninen E., Laulumaa V., Hartikainen P., Länsimies E. Initial experience with single-photon emission tomography using iodine 123-labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane in human brain. European Journal of Nuclear Medicine 1993; 20: 783-786.
11. 123I]β-CIT SPECT. Parkinsonism and Related Disorders 1995; 1: 47-52.
12. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Annals of Neurology 1995; 38: 589-598.
13. Neumeyer J. L., Wang S., Gao Y., et al. N-w-Fluoroalkyl analogs of (1R)-2β-carbomethoxy-3β-(4-iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. Journal of Medical Chemistry 1994; 37: 1558-1561.
14. 123I]N-w-fluoroalkyl-2β-carboxy-3β-(4-iodophenyl)nortropane esters in baboons. Nuclear Medicine and Biology 1995; 22: 211-219.
15. 11C]β-CIT-FP, a potential radioligand for quantitation of the dopamine transporter, preparation, autoradiography, metabolite studies, and positron emission tomography. Nuclear Medicine and Biology 1995; 22: 905-913.
16. Kuikka J. T., Bergström K., Ahonen A., et al. Comparison of iodide-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)-tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. European Journal of Nuclear Medicine 1995; 22: 356-360.
17. 123I]β-CIT binding to dopamine transporters in healthy human subjects. Journal of Cerebral Blood Flow Metabolism and Synapse 1994; 14: 982-994.
18. Hoehn M. D., Yahr M. M. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
19. Fahn, S., Elton, R. L. and the members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In Recent Developments in Parkinson's Disease, Vol. II, ed. S. Fahn, C. D. Marsden, M. Goldstein and D. B. Calne. Macmillan, Florham Park, NJ, 1987, pp. 153-163.
20. 3H]cocaine binding to the dopamine transporter in Parkinson's disease. European Journal of Pharmacology 1983; 95: 145-146.
21. 3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease. Journal of Neurochemistry 1987; 49: 617-621.
22. 3H]GBR-12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. European Journal of Pharmacy 1988; 156: 331-340.
23. Kish S. J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. New England Journal of Medicine 1988; 318: 876-880.
24. 3H]GBR-12935 binding to dopamine uptake sites is decreased in Parkinson's disease and dementia of the Alzheimer type. Brain Research 1994; 637: 262-266.
25. Brooks D. J., Salmon E. P., Mathias C. J., et al. The relationship between locomotor disability, autonomic dysfunction and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure and Parkinson's disease, studied with PET. Brain 1990; 113: 1539-1552.